LONDON, April 19, 2018 /PRNewswire/ --
Leading Companies, Trends and Developments in theGrowing Theranostics Market
What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2018-2028 and other analyses show you commercial prospects Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.
The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market: • Theranostics • Other Companion Diagnostics
Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.
The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics: • US • Germany • France • Italy • Spain • UK • Japan • China • India • Russia • Brazil • South Korea
The report provides detailed profiles of key companies operating within the companion diagnostics market: • F. Hoffmann-La Roche Ltd • Qiagen N.V. • Abbott Laboratories • Agilent Technologies • Myriad Genetics • bioMerieux • Thermo Fisher Scientific
Leading companies and potential for market growth Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2028.
Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these: • F. Hoffmann-La Roche Ltd • Qiagen N.V. • Abbott Laboratories • Agilent Technologies • Myriad Genetics • bioMerieux • Thermo Fisher Scientific
A company profile gives you the following information where available: • Discussion of a company's activities and outlook • Historic revenue, analysis and discussion of company performance over the past 5 years • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the companion diagnostics industry? Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses: • Highly diverse market needing strong knowledge of key therapeutic indications • Changing regulatory landscape challenging new entrants and major market players alike • Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Companion Diagnostics: Market Forecast 2018-2028 report helps you In summary, our 183-page report gives you the following knowledge: • Revenue forecasts to 2028 for the Companion Diagnostics market - discover the industry's prospects, finding promising places for investments and revenues • Revenue forecasts to 2028 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics. • Revenue forecasts to 2028 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea • Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.
To request a report overview of this report please email Sara Peerun at firstname.lastname@example.org or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/2168/The-Companion-Diagnostics-(CDx)-Market-Forecast-2018-2028
Companies and Organisations Mentioned
20/20 Gene Systems
Biogenex Laboratories, Inc.
Brain Resource Company
Cancer Research UK
Caris Life Sciences
Celera (acquired by Quest Diagnostics)
Clinical Reference Laboratory
College of American Pathology (CAP)
European Medicines Agency (EMA)
Inverness Medical Innovations (now known as Alere)
Kimball Genetics (a division of LabCorp)
Kunlun Health Insurance
Laboratory for Personalized Molecular Medicine
Medical Research Council
National Health Insurance (NHI) (South Korea)
Northern Institute for Cancer Research
Oxford BioTherapeutics (earlier Oxford Genome Sciences)
Pacific Diagnostics Clinical Laboratory (ResearchDx)
PICC Health Insurance
Ping An Insurance Group
Quintiles Transnational Corporation
Randox Pharma Services
Resonance Health Analysis Services
Sistema Único de Saúde (SUS)
Takeda's Millennium unit
The Association of British Pharmaceutical Industries
The Food and Drug Administration (FDA)
The Haute Autorité de santé (HAS)
The National Institute for Health and Care Excellence (NICE)
Thermo Fisher Scientific
Third Wave Technologies (Hologic)
Tufts Center for the Study of Drug Development
University of Newcastle
Ventana Medical Systems (a subsidiary of Roche)
Weisenthal Cancer Group
To see a report overview please email Sara Peerun on email@example.com
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All